Evicenter
Darzalex (daratumumab) in Multiple myeloma
Manufacturer
Janssen Biotech, Inc.
Questions
61
Last updated

All questions

Safety: Darzalex (daratumumab) in multiple myeloma

19 questions · 5 sources

Administration reactions

Does Darzalex Faspro cause fewer infusion reactions than Darzalex IV (COLUMBA)?

Applies to Relapsed or refractory multiple myeloma after at least 3 prior lines: DARZALEX FASPRO vs intravenous DARZALEX monotherapy (COLUMBA)

Note: Table 21 columns are DARZALEX FASPRO (N=260) All Grades and Grade ≥3, then intravenous daratumumab (N=258) All Grades and Grade ≥3 (%). The last passage is from the Dosing and Administration Guide; the Darzalex HCP FAQ describes the same COLUMBA comparison as systemic administration-related reactions in 13% (n=260) vs 34% (n=258).

How common are infusion reactions with Darzalex IV?

“DARZALEX can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life-threatening and fatal outcomes have been reported [see Adverse Reactions (6.2)]. In clinical trials (monotherapy and combination: N=2,066), infusion- related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (range: 0 to 73 hours). The incidence of infusion modification due to reactions was 36%. Median durations of 16 mg/kg infusions for the Week 1, Week 2, and subsequent infusions were approximately 7, 4, and 3 hours respectively. Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX. Prior to the introduction of post-infusion medication in clinical trials, infusion-related reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common signs and symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension, and blurred vision [see Adverse Reactions (6.1)].” (opens the source at this quote in a new tab)

Note: The 41% rate is for DRd in MAIA, from the MAIA safety page.

How are Darzalex infusion reactions managed?

How common are Darzalex Faspro injection-site and systemic reactions?

Note: The Important Safety Information on the Darzalex HCP pages gives the multiple myeloma count in the systemic-reaction sentence as N=1235; the Prescribing Information gives N=1253.

Warnings

Can Darzalex cause eye problems such as acute myopia or angle-closure glaucoma?

Does Darzalex increase the risk of low blood counts (neutropenia or thrombocytopenia)?

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the next four are from the DARZALEX FASPRO Prescribing Information. Table 8 (MAIA) columns are DRd (N=364) All Grades, Grade 3, and Grade 4, then Rd (N=365) All Grades, Grade 3, and Grade 4 (%). Table 10 (PERSEUS) columns are DARZALEX FASPRO-VRd All Grades and Grade 3 or 4, then VRd All Grades and Grade 3 or 4 (%).

Does Darzalex increase the risk of serious infections?

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information, whose pooled population includes smoldering multiple myeloma and AL amyloidosis. The third passage is from the MAIA safety section of the DARZALEX Prescribing Information; the cumulative infection rates are from the follow-up safety analysis on the MAIA safety page.

Does Darzalex interfere with blood typing and transfusion tests?

Does Darzalex interfere with myeloma response tests (SPE and immunofixation)?

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the others are from the DARZALEX FASPRO Prescribing Information.

Can Darzalex Faspro cause heart problems in light chain (AL) amyloidosis?

Applies to Light chain (AL) amyloidosis treated with DARZALEX FASPRO + bortezomib, cyclophosphamide, and dexamethasone

Note: Warning 5.2 of the DARZALEX FASPRO label applies to light chain (AL) amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone.

Can Darzalex be used during pregnancy?

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.

How long is contraception needed after the last dose of Darzalex?

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.

Who should not receive Darzalex (contraindications)?

Side effects

What are the most common side effects of Darzalex (DRd) in MAIA?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

Note: Table 7 columns are DRd (N=364) All Grades, Grade 3, and Grade 4, then Rd (N=365) All Grades, Grade 3, and Grade 4 (%). In the decreased appetite row, the label and the DRd All Grades value share one line. Table 8 columns follow the same order.

What are the side effects of Darzalex Faspro with VRd for transplant-ineligible patients (CEPHEUS)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

“The safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide and dexamethasone compared to bortezomib, lenalidomide and dexamethasone (VRd) was evaluated in CEPHEUS in patients with newly diagnosed multiple myeloma who were ineligible for ASCT or refused ASCT as initial therapy [see Clinical Studies (14.1)]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 6, once every 3 weeks from weeks 7 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity in combination with VRd (n=197) or VRd alone (n=195). The median duration of treatment was 56.3 months (0.1 to 64.6 months) for DARZALEX FASPRO-VRd and 34.3 months (0.5 to 63.8 months) for VRd. Serious adverse reactions occurred in 72% of patients who received DARZALEX FASPRO-VRd. The most frequent serious adverse reactions in >5% of patients who received DARZALEX FASPRO-VRd were pneumonia (19%), COVID-19 (12%), thromboembolism (7%), and diarrhea (6%). Fatal adverse reactions occurred in 16.8% of patients who received DARZALEX FASPRO-VRd. Fatal adverse reactions that occurred in more than 1 patient included pneumonia (4%), COVID-19 (4%), and myocardial infarction (2%). Permanent treatment discontinuation due to an adverse reaction occurred in 8% of patients who received DARZALEX FASPRO-VRd. An adverse reaction which resulted in permanent discontinuation of DARZALEX FASPRO-VRd in more than 1 patient included pneumonia. The most common adverse reactions (≥20%) were upper respiratory tract infection, sensory neuropathy, musculoskeletal pain, diarrhea, fatigue, edema, rash, motor dysfunction, COVID-19, constipation, sleep disorder, cough, pneumonia, renal impairment, dizziness, nausea, urinary tract infection, pyrexia, abdominal pain, dyspnea, decreased appetite, and bruising.” (opens the source at this quote in a new tab)

“Table 11: Adverse Reactions Reported in ≥20% of Patients Who Received DARZALEX FASPRO-VRd in CEPHEUS Adverse Reaction DARZALEX FASPRO-VRd (N=197) VRd (N=195) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Infections Upper respiratory tract infectiona 75 4# 63 3# COVID-19b 39@ 9 25@ 3 Pneumoniac 31@ 16 26@ 15 Urinary tract infectionb 24 4# 17 3# Nervous system disorders Sensory neuropathyd 72 12# 72 10 Motor dysfunctione 44 11# 37 7# Dizzinessb 26 2# 26 1# Musculoskeletal and connective tissue disorders Musculoskeletal painb 62 9# 61 7# Table 11: Adverse Reactions Reported in ≥20% of Patients Who Received DARZALEX FASPRO-VRd in CEPHEUS (continued) Adverse Reaction DARZALEX FASPRO-VRd (N=197) VRd (N=195) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Gastrointestinal disorders Diarrheab 57 12# 59 9# Constipation 38 2# 42 3# Nausea 25 0 25 2# Abdominal painb 23@ 1 17 2# General disorders and administration site conditions Fatigueb 56 14# 53 11# Edemab 54 4# 46 2# Pyrexiab 24 1# 16 1# Skin and subcutaneous tissue disorders Rashb 50 8# 47 7 Psychiatric disorders Sleep disorderb 33 3# 33 2# Respiratory, thoracic and mediastinal disorders Coughb 32 1# 21 1# Dyspneab 21@ 2 17 1# Renal and urinary disorders Renal impairmentf 26 7 25 6 Metabolism and nutrition disorders Decreased appetite 21 1# 20 3# Injury, poisoning and procedural complications Bruisingb 20 0 12 0” (opens the source at this quote in a new tab)

Note: Table 11 columns are DARZALEX FASPRO-VRd (N=197) All Grades and Grade 3 or 4, then VRd (N=195) All Grades and Grade 3 or 4 (%).

What are the side effects of Darzalex Faspro with VRd for transplant-eligible patients (PERSEUS)?

Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

“The safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide and dexamethasone (n=351) from the start of induction to the end of consolidation compared to bortezomib, lenalidomide and dexamethasone (VRd) (n=347) was evaluated in PERSEUS [see Clinical Studies (14.1)]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8 and once every 2 weeks from weeks 9 to 16 during induction in combination with VRd or VRd alone. After week 16, patients underwent stem cell mobilization, high dose chemotherapy, and ASCT. Within 12 weeks of ASCT, and when engraftment was complete, patients received DARZALEX FASPRO once every 2 weeks from weeks 1 to 8 during consolidation in combination with VRd or VRd alone. The median duration of treatment for induction and consolidation was 9.9 months (0.5 to 18.5 months) for DARZALEX FASPRO-VRd. Serious adverse reactions occurred in 37% of patients who received DARZALEX FASPRO-VRd. The most frequent serious adverse reaction in >5% of patients who received DARZALEX FASPRO-VRd was pneumonia (6%). Fatal adverse reactions occurred in 1.7% of patients who received DARZALEX FASPRO-VRd. Permanent treatment discontinuation due to an adverse reaction occurred in 2% of patients who received DARZALEX FASPRO-VRd. An adverse reaction which resulted in permanent discontinuation of DARZALEX FASPRO-VRd in more than 1 patient included sepsis. The most common adverse reactions (≥20%) were peripheral neuropathy, fatigue, upper respiratory infection, constipation, musculoskeletal pain, insomnia, rash, diarrhea, edema, and pyrexia.” (opens the source at this quote in a new tab)

Note: Table 9 columns are DARZALEX FASPRO-VRd (N=351) All Grades and Grade 3 or 4, then VRd (N=347) All Grades and Grade 3 or 4 (%), through the end of consolidation.

How many patients stop Darzalex (DRd) because of side effects (MAIA)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

Note: The Safety Over Time page of the Darzalex HCP site reports, in a subset analysis by treatment duration (to approximately 30 months) that is not in the Prescribing Information, has not been evaluated by the FDA, and from which the page states no conclusions should be drawn, that 13% of intent-to-treat patients discontinued treatment due to a TEAE with DARZALEX + Rd (n=364) vs 22% with Rd alone (n=365).

What are the long-term side effects of Darzalex (DRd) in MAIA?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

Note: The first four passages are from the follow-up safety analysis on the MAIA safety page; the last two are from the Safety Over Time page, whose subset analysis covers patients who continued treatment from treatment initiation to approximately 30 months. The most frequent TEAEs of the follow-up analysis appear on the page only as a figure.

What side effects have been reported with Darzalex since approval?

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.